GPX Medical: Continuous Lung Monitoring for Infants in need - Analyst Group

1.1 million infants die annually, where 80% suffer from Respiratory Distress Syndrome (RDS). The problem is extensive, and today there are no real sustainable solutions for monitoring RDS in real-time. GPX Medical AB (publ) (”GPX Medical” or “the Company”) develops the NEOLA®, which allows non-invasive, continuous monitoring of lung volume and oxygen changes in real-time. GPX Medical intends to initiate market launch during 2023, which is estimated to be followed by a rapid sales growth, with revenues reaching 84.4 MSEK in 2026. Based on an applied P/S-multiple of 3x and discount rate of 13%, this yields an equity value per share of 5.1 SEK in a Base scenario. Before market launch, we see several catalysts driving value, where steps in the right direction should reduce the current valuation discount.

Länk till analysen i sin helhet: https://www.analystgroup.se/analyser/gpx-medical-2/